Sponsors (18)
The bill gives law enforcement faster, clearer tools and tougher penalties to target fentanyl analogs and aims to protect public health, but it does so at the cost of restricting research and clinical access, increasing incarceration and taxpayer burdens, and creating legal and administrative uncertainty.
The general public: the bill's class‑based scheduling and enhanced penalties for large shipments aim to reduce the availability of novel fentanyl analogs and potentially lower overdose deaths.
Law enforcement and prosecutors: clearer, drug‑specific quantity thresholds and class‑scheduling give stronger, more consistent legal tools to target large‑scale traffickers and importers/exporters.
Researchers and patients: the bill creates faster, more predictable administrative pathways (HHS binding findings, quicker Schedule I study approvals, multi‑site registrations and continuity provisions) that can speed medical research and potential therapeutic access to certain fentanyl‑related compounds.
Researchers, clinicians, and patients: the broad structure‑based Schedule I classification will restrict research access, complicate clinical study of novel compounds, and create legal hurdles for legitimate scientific work.
Defendants (especially low‑income and marginalized individuals): lower gram thresholds and harsher mandatory penalties can increase mandatory sentences, reduce judicial discretion, and raise the risk of severe punishment for small or dilute quantities.
Taxpayers and the criminal justice system: more prosecutions and longer sentences could expand prison populations and enforcement costs, and class scheduling may shift resources toward prosecuting possession or minor distribution rather than major trafficking.
Based on analysis of 9 sections of legislative text.
Introduced January 31, 2025 by Chris Pappas · Last progress January 31, 2025
Creates a permanent, class-wide Schedule I category for “fentanyl-related substances” based on defined chemical structures, requires publication of listed substances, and changes federal criminal weight thresholds for fentanyl and certain fentanyl analogues. Establishes a binding, expedited HHS-to-Justice rescheduling/removal process for such substances, allows courts to vacate or reduce sentences if a substance is later rescheduled or removed, streamlines Schedule I research registrations and multi-site researcher rules, directs the Attorney General to issue implementing rules within one year, and requires a GAO report within four years evaluating impacts.